Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Receivables (2021 - 2024)

Roivant Sciences (ROIV) has disclosed Receivables for 4 consecutive years, with $678000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables fell 98.35% year-over-year to $678000.0, compared with a TTM value of $678000.0 through Dec 2024, down 98.35%, and an annual FY2024 reading of $678000.0, down 98.35% over the prior year.
  • Receivables was $678000.0 for Q4 2024 at Roivant Sciences, down from $1.9 million in the prior quarter.
  • Across five years, Receivables topped out at $86.2 million in Q1 2021 and bottomed at -$96.6 million in Q2 2021.
  • Average Receivables over 4 years is $20.8 million, with a median of $25.0 million recorded in 2022.
  • The sharpest move saw Receivables surged 683.37% in 2023, then plummeted 98.35% in 2024.
  • Year by year, Receivables stood at $8.9 million in 2021, then skyrocketed by 213.5% to $28.0 million in 2022, then skyrocketed by 46.88% to $41.1 million in 2023, then tumbled by 98.35% to $678000.0 in 2024.
  • Business Quant data shows Receivables for ROIV at $678000.0 in Q4 2024, $1.9 million in Q3 2024, and $79.8 million in Q2 2024.